Raymond James started coverage on shares of Veru (NASDAQ:VERU – Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $3.00 price objective on the stock. Separately, HC Wainwright reissued a buy rating and set a $2.00 target price on shares of […]
Raymond James began coverage on shares of Veru (NASDAQ:VERU – Free Report) in a research note published on Thursday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $3.00 price target on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $2.00 price target on shares of Veru in a […]
Veru (NASDAQ:VERU – Get Free Report) and Sophiris Bio (OTCMKTS:SPHS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations. Insider and Institutional Ownership 47.2% of Veru shares […]
Veru Inc. (NASDAQ:VERU – Free Report) – Equities research analysts at HC Wainwright lifted their Q1 2024 earnings per share estimates for shares of Veru in a note issued to investors on Tuesday, January 9th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.12) per share for the quarter, […]